Vanguard Capital Management’s ArriVent BioPharma AVBP Stock Holding History
Bought
Maintained
Sold
Other funds holding AVBP
IAM
Vanguard Capital Management's AVBP Position: Q3 2026 in Review
Vanguard Capital Management increased its ArriVent BioPharma (AVBP) stake by 13% in Q3 2026, buying an estimated $7.24M and bringing the position to 2,011,253 shares worth $60.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1795.
Vanguard Capital Management first reported a position in AVBP in Q1 2026 and has held it in 3 quarters since. The position peaked at $61.7M in Q2 2026. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.
- Vanguard Capital Management held 2,011,253 shares of ArriVent BioPharma worth $60.9M as of Q3 2026.
- Vanguard Capital Management bought 236,380 ArriVent BioPharma shares in Q3 2026, an estimated $7.24M.
- ArriVent BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1795 holding.
- Vanguard Capital Management first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's ArriVent BioPharma position peaked at $61.7M in Q2 2026.
- 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.